Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones [Yahoo! Finance]
Nuvalent, Inc. - Class A (NUVL)
NASDAQ:AMEX Investor Relations:
nuvelinc.com/company/investor_relations.html
Company Research
Source: Yahoo! Finance
NDA submission for neladalkib in TKI pre-treated advanced ALK-positive NSCLC population planned for the first half of 2026 Submission for potential indication expansion of zidesamtinib in TKI-naïve advanced ROS1-positive NSCLC population planned for the second half of 2026 Well capitalized with operating runway anticipated into 2029 Company to present at 44 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 th at 9:00 a.m. PT CAMBRIDGE, Mass. Jan. 12, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline progress and outlined key anticipated milestones towards its first potential U.S. commercial launch under its "OnTarget 2026" operating plan. As part of this plan, Nuvalent anticipates the following 2026 milestones: Commercial launch in the U.S. of zidesamtinib for the treatment of adult patien
Show less
Read more
Impact Snapshot
Event Time:
NUVL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVL alerts
High impacting Nuvalent, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
NUVL
News
- Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 MilestonesPR Newswire
- Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run [Yahoo! Finance]Yahoo! Finance
- Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare ConferencePR Newswire
- Nuvalent (NASDAQ:NUVL) had its price target lowered by analysts at JPMorgan Chase & Co. from $147.00 to $145.00. They now have an "overweight" rating on the stock.MarketBeat
NUVL
Earnings
- 5/8/25 - Miss
NUVL
Sec Filings
- 1/14/26 - Form 8-K
- 1/7/26 - Form 4
- 1/7/26 - Form 4
- NUVL's page on the SEC website